MX2023005138A - Conjugados dirigidos que comprenden arnpi modificado. - Google Patents
Conjugados dirigidos que comprenden arnpi modificado.Info
- Publication number
- MX2023005138A MX2023005138A MX2023005138A MX2023005138A MX2023005138A MX 2023005138 A MX2023005138 A MX 2023005138A MX 2023005138 A MX2023005138 A MX 2023005138A MX 2023005138 A MX2023005138 A MX 2023005138A MX 2023005138 A MX2023005138 A MX 2023005138A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- modified sirna
- sirna
- targeted conjugates
- targeted
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title abstract 4
- 125000005647 linker group Chemical group 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención proporciona ciertos ácidos nucleicos (p. ej., moléculas de ARNpi de doble cadena), así como conjugados que comprenden un resto de direccionamiento, un ARNpi y grupos de enlace opcionales. Los conjugados son útiles para dirigirse a ARNpi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063110837P | 2020-11-06 | 2020-11-06 | |
PCT/US2021/058232 WO2022098990A1 (en) | 2020-11-06 | 2021-11-05 | Targeted conjugates comprising modified sirna |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005138A true MX2023005138A (es) | 2023-06-23 |
Family
ID=81457390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005138A MX2023005138A (es) | 2020-11-06 | 2021-11-05 | Conjugados dirigidos que comprenden arnpi modificado. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240052349A1 (es) |
EP (1) | EP4240369A1 (es) |
JP (1) | JP2023548295A (es) |
KR (1) | KR20230104652A (es) |
CN (1) | CN116472063A (es) |
AU (1) | AU2021376390A1 (es) |
CA (1) | CA3199757A1 (es) |
IL (1) | IL302530A (es) |
MX (1) | MX2023005138A (es) |
TW (1) | TW202233243A (es) |
WO (1) | WO2022098990A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024099316A1 (zh) * | 2022-11-08 | 2024-05-16 | 南京明德新药研发有限公司 | 含七元杂环的四价缀合基团及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222064A1 (en) * | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
WO2011139710A1 (en) * | 2010-04-26 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
BR112019021359A2 (pt) * | 2017-04-11 | 2020-05-05 | Arbutus Biopharma Corp | moléculas, composições, compostos, métodos para administrar um sirna, para preparar um composto e para tratar uma infecção, composto ou sal, conjugado de galnac e uso de um composto |
US11324820B2 (en) * | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
-
2021
- 2021-11-05 EP EP21890140.3A patent/EP4240369A1/en active Pending
- 2021-11-05 WO PCT/US2021/058232 patent/WO2022098990A1/en active Application Filing
- 2021-11-05 CN CN202180078408.9A patent/CN116472063A/zh active Pending
- 2021-11-05 KR KR1020237018346A patent/KR20230104652A/ko unknown
- 2021-11-05 IL IL302530A patent/IL302530A/en unknown
- 2021-11-05 CA CA3199757A patent/CA3199757A1/en active Pending
- 2021-11-05 JP JP2023525517A patent/JP2023548295A/ja active Pending
- 2021-11-05 AU AU2021376390A patent/AU2021376390A1/en active Pending
- 2021-11-05 US US18/035,695 patent/US20240052349A1/en active Pending
- 2021-11-05 MX MX2023005138A patent/MX2023005138A/es unknown
- 2021-11-08 TW TW110141540A patent/TW202233243A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL302530A (en) | 2023-07-01 |
AU2021376390A1 (en) | 2023-06-22 |
CN116472063A (zh) | 2023-07-21 |
KR20230104652A (ko) | 2023-07-10 |
US20240052349A1 (en) | 2024-02-15 |
JP2023548295A (ja) | 2023-11-16 |
CA3199757A1 (en) | 2022-05-12 |
TW202233243A (zh) | 2022-09-01 |
WO2022098990A1 (en) | 2022-05-12 |
EP4240369A1 (en) | 2023-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502333A1 (en) | Targeted compositions | |
NZ747138A (en) | Targeted nucleic acid conjugate compositions | |
CY1119183T1 (el) | Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων | |
AU2018320870A1 (en) | RNA targeting methods and compositions | |
CY1120174T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη εκφρασης τρανσθυρετινης | |
EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
EP4218802A3 (en) | Conjugates for targeted cell surface editing | |
MX2023001541A (es) | Administracion sistemica de oligonucleotidos. | |
PE20190844A1 (es) | Modulacion de transcripcion con arn de direccion a adn generico | |
ATE534737T1 (de) | Gezielte abgabe von sirna | |
AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
AU2009236219A8 (en) | Silencing of CSN5 gene expression using interfering RNA | |
EA202090744A1 (ru) | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии | |
BR112021024080A2 (pt) | Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos | |
MX2023005138A (es) | Conjugados dirigidos que comprenden arnpi modificado. | |
EP4219527A3 (en) | Adenoviruses and methods for using adenoviruses | |
CA2876165C (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
MX2019014415A (es) | Compuesto monomerico de acido nucleico modificado y analogo de acido oligonucleico. | |
WO2022187435A8 (en) | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof | |
MX2022006846A (es) | Conjugados y metodos para tratar la fibrosis hepatica. | |
WO2022120388A3 (en) | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | |
UY37936A (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 | |
BR112022010839A2 (pt) | Compostos heterocíclicos funcionalizados como moduladores de estimulador de genes de interferon (sting) | |
AR098819A1 (es) | Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry | |
PH12020551599A1 (en) | Systems, methods and composition of using rnase iii mutants to produce srna to control host pathogen infection |